(Abst.) Tysabri better than Gilenya in achieving "no evidence of disease activity" on: November 10, 2020, 08:38:32 pm #1 From PubMed (October 30, 2020), "BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS": BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS - PubMed BEST-MS is a prospective study that compared head-to-head the effectiveness of NTZ and FTY in active relapsing-remitting MS. Our results suggest a superiority of NTZ over FTY. PubMed · pubmed.ncbi.nlm.nih.gov Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
